Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression

• Gloria Perazzoli ,

  Contributed equally to this work with: Gloria Perazzoli, Raul Ortiz

  Affiliation Institute of Biopathology and Regenerative Medicine (IBIMER), Granada, Spain

  ⨯
• Jose Prados ,

  * E-mail: jcprados@ugr.es

  Affiliations Institute of Biopathology and Regenerative Medicine (IBIMER), Granada, Spain, Biosanitary Institute of Granada (ibs.GRANADA), SAS-Universidad de Granada, Granada, Spain

  ⨯
• Raul Ortiz ,

  Contributed equally to this work with: Gloria Perazzoli, Raul Ortiz

  Affiliation Department of Health Science, University of Jaén, Jaén, Spain

  ⨯
• Octavio Caba,

  Affiliation Department of Health Science, University of Jaén, Jaén, Spain

  ⨯
• Laura Cabeza,

  Affiliation Institute of Biopathology and Regenerative Medicine (IBIMER), Granada, Spain

  ⨯
• Maria Berdasco,

  Affiliation Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain

  ⨯
• Beatriz Gónzalez,

  Affiliation Service of Medical Oncology, San Cecilio Hospital, Granada, Spain

  ⨯
• Consolación Melguizo

  Affiliations Institute of Biopathology and Regenerative Medicine (IBIMER), Granada, Spain, Biosanitary Institute of Granada (ibs.GRANADA), SAS-Universidad de Granada, Granada, Spain

  ⨯